Novo Nordisk has promoted Rishang Deoras to Global Director - Diabetes Commercial Unit.Deoras shared the news in a LinkedIn ...

China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk ... along with the rest of the world. Camilla Sylvest, senior vice president for China region ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over ...

Analyst downgrades Novo Nordisk, cuts price target to $64. The analyst highlights that Lilly's drugs, Mounjaro and Zepbound, will gain U.S. market share from Novo Nordisk's Ozempic and Wegovy.

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer ...

Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is ...

Representative C. Scott Franklin (R-Florida) recently bought shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on April 11th, the Representative disclosed that they had bought between $ ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over ...